



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: P. A. Billing-Medel, *et al.*

Serial No.: 09/092,297

Filed: June 5, 1998

For: REAGENTS AND METHODS USEFUL
FOR DETECTING DISEASES OF THE
URINARY TRACT

Case No.: 6107.US.P1

Examiner: L. Turner

Group Art Unit: 1647

Date: January 23, 2003

CERTIFICATE OF MAILING (37 CFR 1.8(a))

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:

Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: January 28, 2003


Wanda E. Smith

STATEMENT UNDER 37 C.F.R. §1.821-1.825

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned, being the agent of record of the above-identified patent application,
submits the following statement regarding the Sequence Listing in computer readable (submitted
herewith) and paper form:

I hereby state that the content of the paper and computer readable copies of the Sequence
Listing, are the same; and that they contain no sequence information that would constitute new
matter beyond the original submissions.



23492


ABBOTT LABORATORIES
Telephone: (847) 938-3137
Facsimile: (847) 938-2623

Wood, Phillips, Katz, Mortimer & Clark
500 West Madison Street
Suite 3800
Chicago, IL 60662-2511
Phone: (312) 876-2109
Fax: (312) 876-2020


Respectfully submitted,

P. A. Billing-Medel, *et al.*

Mimi C. Goller
Registration No. 39,046
Attorney for Applicants



Lisa V. Mueller
Registration No. 38,978
Attorney for Applicants



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: *claims 33 and 39 recite the sequence 819141 without reference to an appropriate sequence identifier.*

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY